Mendus Launches Early-stage Trial for Acute Myeloid Leukemia Treatment Combo

05:24 AM EDT, 09/16/2026 (MT Newswires) -- Mendus (IMMU.ST) said Wednesday that it began the phase 1b study for its acute myeloid leukemia, or AML, combo treatment. The Diva study will review the safety and immune activity of AML patients with measurable residual disease dosed with vididencel in combination with venetoclax and azacitidine. Additionally, the study aims to see if there is a decrease in measurable residual disease among patients. The biopharmaceutical company expects a safety readout to be published in the first half of 2027, with initial topline data release in the second half of 2027.